payday loans
payday loans
Skip to content

Accueil FMC Immunotherapeutic Interleukin-6 or Interleukin-6 receptor blockade in cancer: challenges and opportunities.
Immunotherapeutic Interleukin-6 or Interleukin-6 receptor blockade in cancer: challenges and opportunities. Imprimer Envoyer
Lundi, 17 Juillet 2017 07:24

Immunotherapeutic Interleukin-6 or Interleukin-6 receptor blockade in cancer: challenges and opportunities.

Curr Med Chem. 2017 Jul 12;:

Authors: Kampan NC, Xiang SD, McNally OM, Stephens AN, Quinn MA, Plebanski M

Abstract
Interleukin 6 (IL-6), a well-known pro-inflammatory cytokine with pleiotropic activity is a central player in chronic inflammatory diseases including cancers. Therefore, blockade of the IL-6 signaling pathway has become a target for the therapy of in diverse cancers such as multicentric Castleman's disease (CD), multiple myeloma and solid tumours including renal, prostate, lung, colorectal and ovarian cancers. Monoclonal antibodies against IL-6 (Siltuximab) and the IL-6 receptor (IL-6R) (Tocilizumab) have emerged as potential immunotherapies, alone or in combination with conventional chemotherapy. Human trials have demonstrated the ability to block IL-6 activity and in multicentric CD lead to durable clinical response and longer disease stabilisation. However, the efficacy of these treatments is still debatable for other cancers. New generation therapeutics in development such as Clazakizumab, Sarilumab, and soluble gp130Fc has the additional features of improved binding affinity, better specificity with reduced adverse effects. A deeper understanding of the immunological basis of these agents, as well as of the challenges that are faced by immunotherapy-based products in clinical trials, will help select the most promising anti-IL-6/IL-6R therapies for large scale use. Concurrently, current research efforts to personalize treatments, may help in treatment of patients that would greatly benefit from IL-6 blocking therapies.

PMID: 28707587 [PubMed - as supplied by publisher]


Author:

Read Full Article
 

find-us-on-facebook-2

United4LungHealth

image001

World Allergy Week 2017 The Agony of Hives

WCOPDday2017



PubMed Logo
Word

 To: 

Langtolang Dictionary

CNP2017

50x50_firefoxsafari_iconGchrome

Notre site est optimisé pour les Navigateurs suivants : Firefox, Safari et Google Chrome. Cliquez sur l'un des logos ci-dessus pour le télécharger et l'installer gratuitement.

Tabac

Accueil FMC Immunotherapeutic Interleukin-6 or Interleukin-6 receptor blockade in cancer: challenges and opportunities. Top